News

Therapy resistance decoded
Enlarge image

ScienceFrance

Therapy resistance decoded

03.12.2012 - French researchers have identified how the body’s immune systems triggers therapy resistance to the cancer drugs gemcitabine and 5-fluorouracil.

The researchers, headed by François Ghiringhelli from INSERM in Dijon, found that in mice, the drugs activate a protein complex, termed Nlrp3 inflammasome, in myeloid derived suppressor cells. This activation leads to the release of the immune cell interleukin (IL)-1 beta, which then skews T immune cells to produce protumorigenic IL-17 and results in enhanced growth of tumours in mice (Nature Medicine, doi: 10.1038/nm.2999). 

The chemotherapeutics were more efficacious at inhibiting tumour growth in mice lacking Nlrp3 or IL-17, or treated with an IL-1 receptor antagonist. The findings suggest that targeting the inflammasome pathway in conjunction with chemotherapy may improve its tumour killing efficacy by preventing the induction of protumorigenic immune responses.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2012-04/therapy-resistance-decoded.html

BusinessGermany

19.09.2014 In order to concentrate on the life science business, German industry giant Bayer is splitting off its plastics subgroup as a separate company.

FinanceSwitzerland

18.09.2014 Swiss biopharma Cardiorentis has received a €45m investment from overseas investment firm Healthcare Royalty Partners in order to finance the registration for its heart drug.

PoliticsEU

15.09.2014 Jean Claude Juncker, the European Commission President-elect revealed his new Commissioners last week, whilst announcing a change in the units dealing with medicines, medical devices and health technology.

BiosimilarsGermanyFrance

12.09.2014 The 2011 collaboration of Boehringer Ingelheim and Eli Lilly is bearing fruit. An insulin biosimilar developed through the partnership has now been approved in Europe - the first-ever generic version of this class.

FinancingNetherlands

11.09.2014 Cystic fibrosis specialist Proqr Therapeutics has set the terms for its upcoming IPO at US-American stock exchange NASDAQ.

Clinical TrialsUKSweden

09.09.2014 In the midst of the hustle and bustle of the European Respiratory Society’s International Congress 2014, Astrazeneca quietly announced the disappointing results of its latest benralizumab study.

BusinessDenmark

04.09.2014 After their arthritis product’s Phase IIb failure, Novo Nordisk A/S is pulling out of all research and development activities within inflammatory disorders.

BusinessBelgiumIrelandSwitzerland

02.09.2014 In the face of declining revenue, Belgian biopharmaceutical company Thrombogenics has decided to spin out its cancer research and development activities.

ResearchUKSwitzerlandItaly

29.08.2014 Just a week ago, Glaxosmithkline defused the WHO’s claim that an Ebola vaccine could be ready by 2015. Now, the British company’s own candidate vaccine is to be rushed to human trials with the help of funding from an international consortium.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • 4SC1.17 EUR0.00%
  • ACTELION109.60 CHF0.00%
  • ADDEX3.10 CHF0.00%

FLOP

  • CYTOTOOLS31.45 EUR-0.47%
  • 4SC1.17 EUR0.00%
  • ACTELION109.60 CHF0.00%

TOP

  • CO.DON3.32 EUR32.8%
  • EPIGENOMICS3.83 EUR23.5%
  • PAION3.05 EUR23.0%

FLOP

  • ADDEX3.10 CHF-22.5%
  • EVOTEC3.08 EUR-16.1%
  • MEDIGENE3.93 EUR-15.5%

TOP

  • SANTHERA88.05 CHF2058.1%
  • CO.DON3.32 EUR286.0%
  • PAION3.05 EUR202.0%

FLOP

  • CYTOS0.24 CHF-94.0%
  • BIOFRONTERA2.20 EUR-39.7%
  • MERCK KGAA68.48 EUR-39.7%

No liability assumed, Date: 21.09.2014